Age-Dependent Effects of COVID-19 Vaccine and of Healthcare Burden on COVID-19 Deaths, Tokyo, Japan

Overview

Journal Emerg Infect Dis

Specialty Infectious Diseases

Date 2022 Jul 12

PMID 35820166

Authors

Yura K Ko

Hiroaki Murayama

Lisa Yamasaki

Ryo Kinoshita

Motoi Suzuki

Hiroshi Nishiura

Affiliations

Soon will be listed here.

Abstract

COVID-19 vaccine effectiveness against death in Japan remains unknown. Furthermore, although evidence indicates that healthcare capacity influences case-fatality risk (CFR), it remains unknown whether this relationship is mediated by age. With a modeling study, we analyzed daily COVID-19 cases and deaths during January-August 2021 by using Tokyo surveillance data to jointly estimate COVID-19 vaccine effectiveness against death and age-specific CFR. We also examined daily healthcare operations to determine the association between healthcare burden and age-specific CFR. Among fully vaccinated patients, vaccine effectiveness against death was 88.6% among patients 60-69 years of age, 83.9% among patients 70-79 years of age, 83.5% among patients 80-89 years of age, and 77.7% among patients >90 years of age. A positive association of several indicators of healthcare burden with CFR among patients >70 years of age suggested an age-dependent effect of healthcare burden on CFR in Japan.

Citing Articles

State-space modelling using wastewater virus and epidemiological data to estimate reported COVID-19 cases and the potential infection numbers.

Kadoya S, Li Y, Wang Y, Katayama H, Sano D J R Soc Interface. 2025; 22(222):20240456.

PMID: 39772733 PMC: 11706650. DOI: 10.1098/rsif.2024.0456.

Global burden of subarachnoid hemorrhage among adolescents and young adults aged 15-39 years: A trend analysis study from 1990 to 2021.

Liu X, Cheng R, Song Y, Yang X, Niu X, Wang C PLoS One. 2024; 19(12):e0316111.

PMID: 39705242 PMC: 11661650. DOI: 10.1371/journal.pone.0316111.

COVID-19 fatality and DALYs, and associated metabolic disorders and ambient air pollutants in pre-Omicron era of the pandemic: an international comparative study.

Ngatu N, Tonduangu D, Munyeshyaka E, Hirao T, Balenda G, Yamadori Y Environ Health Prev Med. 2024; 29:24.

PMID: 38599849 PMC: 11016372. DOI: 10.1265/ehpm.23-00350.

Assessing the COVID-19 vaccination program during the Omicron variant (B.1.1.529) epidemic in early 2022, Tokyo.

Kayano T, Nishiura H BMC Infect Dis. 2023; 23(1):748.

PMID: 37907865 PMC: 10619277. DOI: 10.1186/s12879-023-08748-1.

Evaluating the COVID-19 vaccination program in Japan, 2021 using the counterfactual reproduction number.

Kayano T, Ko Y, Otani K, Kobayashi T, Suzuki M, Nishiura H Sci Rep. 2023; 13(1):17762.

PMID: 37853098 PMC: 10584853. DOI: 10.1038/s41598-023-44942-6.

References

Khan J, Awan N, Islam M, Muurlink O . Healthcare Capacity, Health Expenditure, and Civil Society as Predictors of COVID-19 Case Fatalities: A Global Analysis. Front Public Health. 2020; 8:347. PMC: 7349997. DOI: 10.3389/fpubh.2020.00347. View

Sheikh A, Robertson C, Taylor B . BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant. N Engl J Med. 2021; 385(23):2195-2197. PMC: 8552534. DOI: 10.1056/NEJMc2113864. View

Kayano T, Nishiura H . A Comparison of Case Fatality Risk of COVID-19 between Singapore and Japan. J Clin Med. 2020; 9(10). PMC: 7602812. DOI: 10.3390/jcm9103326. View

Young-Xu Y, Korves C, Roberts J, Powell E, Zwain G, Smith J . Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans. JAMA Netw Open. 2021; 4(10):e2128391. PMC: 8495523. DOI: 10.1001/jamanetworkopen.2021.28391. View

Murayama H, Kayano T, Nishiura H . Estimating COVID-19 cases infected with the variant alpha (VOC 202012/01): an analysis of screening data in Tokyo, January-March 2021. Theor Biol Med Model. 2021; 18(1):13. PMC: 8286039. DOI: 10.1186/s12976-021-00146-x. View

Li X, Hu M, Zheng R, Wang Y, Kang H, Jiang L . Delayed Initiation of ECMO Is Associated With Poor Outcomes in Patients With Severe COVID-19: A Multicenter Retrospective Cohort Study. Front Med (Lausanne). 2021; 8:716086. PMC: 8481658. DOI: 10.3389/fmed.2021.716086. View

Asch D, Sheils N, Nazmul Islam M, Chen Y, Werner R, Buresh J . Variation in US Hospital Mortality Rates for Patients Admitted With COVID-19 During the First 6 Months of the Pandemic. JAMA Intern Med. 2020; 181(4):471-478. PMC: 7756246. DOI: 10.1001/jamainternmed.2020.8193. View

Orfali K . What Triage Issues Reveal: Ethics in the COVID-19 Pandemic in Italy and France. J Bioeth Inq. 2020; 17(4):675-679. PMC: 7651791. DOI: 10.1007/s11673-020-10059-y. View

Grosso F, Presanis A, Kunzmann K, Jackson C, Corbella A, Grasselli G . Decreasing hospital burden of COVID-19 during the first wave in Regione Lombardia: an emergency measures context. BMC Public Health. 2021; 21(1):1612. PMC: 8414029. DOI: 10.1186/s12889-021-11669-w. View

10.

Nunes B, Rodrigues A, Kislaya I, Cruz C, Peralta-Santos A, Lima J . mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of national health registries in Portugal, February to August 2021. Euro Surveill. 2021; 26(38). PMC: 8462036. DOI: 10.2807/1560-7917.ES.2021.26.38.2100833. View

11.

Mizumoto K, Endo A, Chowell G, Miyamatsu Y, Saitoh M, Nishiura H . Real-time characterization of risks of death associated with the Middle East respiratory syndrome (MERS) in the Republic of Korea, 2015. BMC Med. 2015; 13:228. PMC: 4588253. DOI: 10.1186/s12916-015-0468-3. View

12.

Nishiura H, Klinkenberg D, Roberts M, Heesterbeek J . Early epidemiological assessment of the virulence of emerging infectious diseases: a case study of an influenza pandemic. PLoS One. 2009; 4(8):e6852. PMC: 2729920. DOI: 10.1371/journal.pone.0006852. View

13.

Ito K, Piantham C, Nishiura H . Predicted dominance of variant Delta of SARS-CoV-2 before Tokyo Olympic Games, Japan, July 2021. Euro Surveill. 2021; 26(27). PMC: 8268651. DOI: 10.2807/1560-7917.ES.2021.26.27.2100570. View

14.

Bruxvoort K, Sy L, Qian L, Ackerson B, Luo Y, Lee G . Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study. Lancet Reg Health Am. 2021; 6:100134. PMC: 8614600. DOI: 10.1016/j.lana.2021.100134. View

15.

Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S . Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021; 385(7):585-594. PMC: 8314739. DOI: 10.1056/NEJMoa2108891. View